Similarly, Rozanolixizumab (NCT03861481) and the fully human anti-FcRn mAb Batoclimab are under investigation in clinical trials for treatment of CIDP. The gene discussed is FCGRT; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.